Lead Product(s) : DiNA-001
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Sponsor : BioMarin Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The license initially covers DiNAQOR's lead program, DiNA-001 for MYBPC3 hypertrophic cardiomyopathy. Additionally, the companies will collaborate on several of DiNAQOR's other pipeline programs.
Product Name : DiNA-001
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 05, 2020
Lead Product(s) : DiNA-001
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Sponsor : BioMarin Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Rimtuzalcap
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Phase 2 trial is a multicenter, randomized, placebo-controlled study that will evaluate the safety and efficacy of CAD-1883. Efficacy outcome measures.
Product Name : CAD-1883
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 23, 2020
Lead Product(s) : Rimtuzalcap
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable